{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-034547","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.282678+00:00","generated_at":"2026-06-09T21:48:19.871330+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"X4 Pharmaceuticals appoints industry veteran R. Keith Woods to Board of Directors","bullets":["Woods appointed as independent Class II director effective Oct 16, 2023, term through 2025 annual meeting.","He brings 30+ years life science experience, most recently COO of argenx, leading rare disease global launch.","Received initial equity award of 90,000 RSUs vesting equally over 3 years; accelerated on change of control.","No family relationships or material interests with directors/officers; standard indemnification agreement entered.","Appointment follows recent U.S. regulatory submission of X4's first drug candidate (mavorixafor) for WHIM syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-034547","json":"https://secwatch.observer/filing/0001628280-23-034547.json","markdown":"https://secwatch.observer/filing/0001628280-23-034547.md","text":"https://secwatch.observer/filing/0001628280-23-034547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/0001628280-23-034547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/xfor-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:48:19.871330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a42dc83540","claim":"Keith Woods was appointed as Director at X4 Pharmaceuticals, Inc.","evidence_excerpt":"On October 16, 2023, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Keith Woods as a member of the Company’s Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/0001628280-23-034547-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}